Control Bionics Limited (ASX:CBL)

Australia · Delayed Price · Currency is AUD

0.0650

+0.0010 (1.56%)

Oct 7, 2026, 2:51 PM AEST

Market Cap	35.30M +218.0%
Revenue (ttm)	4.77M -22.4%
Net Income	-7.27M
EPS	-0.02
Shares Out	543.09M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	400,629
Open	0.0660
Previous Close	0.0640
Day's Range	0.0650 - 0.0660
52-Week Range	0.0320 - 0.0950
Beta	0.06
Analysts	n/a
Price Target	n/a
Est. Earnings	Nov 24, 2026

About Control Bionics

Control Bionics Limited, together with its subsidiaries, engages in the research, development, commercialization, and sale of assistive communications technology systems in Australia, North America, Japan, and internationally. It offers NeuroNode Trilogy, NeuroNode Duo, and Eye-gaze Duo systems that allow people with speech and movement difficulties to control a computer for speech generation, electronic communications, entertainment, and external control of other devices. The company also provides the NeuroStrip, a wearable, miniaturized elect... [Read more]

Industry Medical Devices

Sector Healthcare

Founded 2005

Country Australia

Stock Exchange Australian Securities Exchange

Ticker Symbol CBL

Full Company Profile

Financial Performance

In fiscal year 2026, Control Bionics's revenue was 4.77 million, a decrease of -22.43% compared to the previous year's 6.14 million. Losses were -7.27 million, 18.9% more than in 2025.

Financial Statements